# BridgeBio Oncology Therapeutics, Inc.: Form 8-K, filed Feb 14, 2024

- Company: [BridgeBio Oncology Therapeutics, Inc.](/companies/bbot.md) (CIK 1869105)
- Form: 8-K
- Filed: 2024-02-14
- Accepted by EDGAR: Feb 14, 2024, 07:35 ET
- Period: 2024-02-08
- Accession: 0001213900-24-013637
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/ea193423-8k_helixacq2.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 3.02: Unregistered sale of equity
- Item 5.02: Departure or appointment of officers or directors
- Item 5.03: Amendment to articles or bylaws
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/ea193423-8k_helixacq2.htm

Filed Feb 14, 2024.
Source: SEC EDGAR, the filing index for accession 0001213900-24-013637. Last ingested by Listed: Nov 5, 2026, 16:25 ET. No prices; not investment advice.